How Dr. Daniel Brennan uses diverse approaches to dd-cfDNA surveillance - immunosuppression modulation and tracking total dd-cfDNA over time

In this episode of our Inside the ProActive Study Podcast, Dr. Daniel Brennan gives us his thoughts on: • Why “50% of DSA’s are clinically meaningless” when monitoring for rejection. • His dd-cfDN

Listen Now

How Dr. Millie Samaniego bridged the gap between study use and routine care by extending protocolized use

In this episode of our Inside the ProActive Study Podcast, Dr. Millie Samaniego-Picota tells us about: • Her experience expanding the ProActive Study Protocol schedule to all her patients • How her

Listen Now

7 days ago

How Dr. Daniel Brennan uses diverse approaches to dd-cfDNA surveillance - immunosuppression modulation and tracking total dd-cfDNA over time

In this episode of our Inside the ProActive Study Podcast, Dr. Daniel Brennan gives us his thoughts on: • Why “50% of DSA’s are clinically meaningless” when monitoring for rejection. • His dd-cfDNA su

Watch Video

18 days ago

How Dr. Millie Samaniego bridged the gap between study use and routine care by extending protocolized use

In this episode of our Inside the ProActive Study Podcast, Dr. Millie Samaniego-Picota tells us about: • Her experience expanding the ProActive Study Protocol schedule to all her patients • How her

Watch Video

27 days ago

How Dr. Yasir Qazi embraced cell-free DNA surveillance, an unaffected approach due to the recent CMS update

Hear from our ProActive Study Investigator In this episode of our Inside the ProActive Study Podcast, Dr. Yasir Qazi talks to us about: • His dd-cfDNA “surveillance journey” and protocol development.

Watch Video

about 1 month ago

How Dr. Matthew Cooper leverages dd-cfDNA to replace protocol biopsies for surveillance, in-line with ASTS recommended use

Listen Now

about 1 month ago

How Dr. Matthew Cooper leverages dd-cfDNA to replace protocol biopsies for surveillance, in-line with ASTS recommended use

In this episode of our Inside the ProActive Study Podcast, Dr. Matthew Cooper shares his insights on: • Utilizing cfDNA alongside DSA and biopsies before implementing his dd-cfDNA surveillance protoc

Watch Video

about 2 months ago

HIPAA Authorization to Release Records to a Partner/Significant-other

about 2 months ago

How Dr. Yasir Qazi embraced cell-free DNA surveillance, an unaffected approach due to the recent CMS update

Hear from our ProActive Study Investigator In this episode of our Inside the ProActive Study Podcast, Dr. Yasir Qazi talks to us about his dd-cfDNA “surveillance journey” and protocol development.

Listen Now

about 2 months ago

OH Patient Portal - Patient Slim Jim

2 months ago

Interim analysis on the variability and stability of cfDNA in the first year post-transplant

Listen to Dr. Matthew Cooper, an Investigator in the ProActive Study, discuss how serial use of Prospera™ provided strong differentiation of patients with allograft stability (low Prospera™ levels) vs

Watch Video

3 months ago

Dd-cfDNA as a prognostic biomarker for rejection - Data from the ProActive Study

Listen to Dr. Jonathan Bromberg, ProActive Study's lead Investigator, discuss how Prospera™ accurately predicted ABMR and TCMR before biopsy-proven rejection, up to 4 months and 2 months in advan

Watch Video